Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 9(1): 5153, 2019 03 26.
Article in English | MEDLINE | ID: mdl-30914732

ABSTRACT

The median eminence (ME) anatomically consists of external (eME) and internal (iME) layers. The hypothalamic neurosecretory cells terminate their axons in the eME and secrete their neurohormones regulating anterior pituitary hormone secretion involved in stress responses into the portal vein located in the eME. Magnocellular neurosecretory cells (MNCs) which produce arginine vasopressin (AVP) and oxytocin in the paraventricular (PVN) and supraoptic nuclei (SON) terminate their axons in the posterior pituitary gland (PP) through the iME. Here, we provide the first evidence that oestrogen modulates the dynamic changes in AVP levels in the eME axon terminals in female rats, using AVP-eGFP and AVP-DREADDs transgenic rats. Strong AVP-eGFP fluorescence in the eME was observed at all oestrus cycle stages in adult female rats but not in male transgenic rats. AVP-eGFP fluorescence in the eME was depleted after bilateral ovariectomy but re-appeared with high-dose 17ß-oestradiol. AVP-eGFP fluorescence in the MNCs and PP did not change significantly in most treatments. Peripheral clozapine-N-oxide administration induced AVP-DREADDs neurone activation, causing a significant increase in plasma corticosterone levels in the transgenic rats. These results suggest that stress-induced activation of the hypothalamic-pituitary-adrenal axis may be caused by oestrogen-dependent upregulation of AVP in the eME of female rats.


Subject(s)
Arginine Vasopressin/pharmacology , Axons/metabolism , Estradiol/pharmacology , Hypothalamo-Hypophyseal System/metabolism , Median Eminence/metabolism , Pituitary-Adrenal System/metabolism , Animals , Female , Hypothalamo-Hypophyseal System/cytology , Male , Oxytocin/pharmacology , Pituitary-Adrenal System/cytology , Rats , Rats, Transgenic , Rats, Wistar
2.
PLoS One ; 13(10): e0202247, 2018.
Article in English | MEDLINE | ID: mdl-30379815

ABSTRACT

OBJECTIVE: We investigated the effects of a single instance of caffeine intake on neurocognitive functions and driving performance in healthy subjects using an established cognitive battery and a driving simulator system. METHODS: This study was conducted in a double-blind, randomized, placebo-controlled manner from February 19, 2016 to August 6, 2016. Caffeine intake was discontinued 3 days prior to the study. Participants were randomly assigned to receive 200-mg doses of caffeine or a placebo. Thirty minutes after administration, cognitive functions were evaluated via the Symbol Digit Coding Test (SDC), the Stroop Test (ST), the Shifting Attention Test (SAT) and the Four Part Continuous Performance Test (FPCPT). After the cognitive function tests were conducted, driving performance was evaluated using a driving simulator. We measured the brake reaction time (BRT) in the Harsh-braking test and the standard deviation of the lateral position (SDLP) in the Road-tracking test. RESULTS: Of 100 randomized subjects, 50 (50%) of 100 in the caffeine group and 50 (50%) of 100 in the placebo group completed the study. Participants in the caffeine group had more correct responses than participants in the placebo group on the SAT (P = 0.03) and made fewer errors (P = 0.02). Participants in the caffeine group exhibited shorter times in the Harsh-braking test than participants in the placebo group (P = 0.048). CONCLUSIONS: A single instance of caffeine intake changed some neurocognitive functions and driving performance in healthy volunteers. TRIAL REGISTRATION: UMIN000023576.


Subject(s)
Attention/drug effects , Caffeine/administration & dosage , Cognition/drug effects , Psychomotor Performance/drug effects , Adult , Attention/physiology , Cognition/physiology , Double-Blind Method , Female , Healthy Volunteers , Humans , Male , Middle Aged , Neuropsychology , Psychomotor Performance/physiology , Reaction Time/drug effects
3.
Int J Mol Sci ; 18(3)2017 Mar 06.
Article in English | MEDLINE | ID: mdl-28272307

ABSTRACT

Aripiprazole has been reported to exert variable effects on cognitive function in patients with schizophrenia. Therefore, in the present study, we evaluated biological markers, clinical data, and psychiatric symptoms in order to identify factors that influence cognitive function in patients with schizophrenia undergoing aripiprazole treatment. We evaluated cognitive function in 51 patients with schizophrenia using Brief Assessment of Cognition in Schizophrenia (BACS), as well as background information, psychiatric symptoms, plasma catecholamine metabolites-homovanillic acid (HVA), 3-methoxy-4-hydroxyphenylglycol (MHPG)-, and serum brain-derived neurotrophic factor (BDNF). Multivariate analyses were performed in order to identify factors independently associated with cognitive function. Brain-derived neurotrophic factor levels, number of hospitalizations, and MHPG levels were associated with verbal memory and learning. Total hospitalization period and MHPG levels were associated with working memory. Age at first hospitalization and education were associated with motor speed. The number of hospital admissions, Positive and Negative Syndrome Scale negative subscale scores (PANSS-N), MHPG levels, BDNF levels, and Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) scores were associated with verbal fluency. Homovanillic acid and MHPG levels, duration of illness, and PANSS-N scores were associated with attention and processing speed. Brain-derived neurotrophic factor and MHPG levels were associated with executive function. These results suggest that treatment of psychiatric symptoms and cognitive dysfunction may be improved in patients treated with aripiprazole by controlling for these contributing factors.


Subject(s)
Antipsychotic Agents/adverse effects , Aripiprazole/adverse effects , Brain-Derived Neurotrophic Factor/blood , Cognition/drug effects , Homovanillic Acid/blood , Methoxyhydroxyphenylglycol/blood , Schizophrenia/blood , Adult , Antipsychotic Agents/therapeutic use , Aripiprazole/therapeutic use , Biomarkers/blood , Executive Function/drug effects , Female , Humans , Male , Memory, Short-Term/drug effects , Middle Aged , Schizophrenia/drug therapy
6.
Cancer Genet Cytogenet ; 177(1): 55-8, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17693192

ABSTRACT

We report on a case of a solitary fibrous tumor that developed in the thigh of an 82-year-old woman. The tumor was composed of areas of high-grade sarcoma and typical solitary fibrous tumor. Its karyotype was: 70,XXX,+X[4],+1[2],add(1)(p36)[4],add(1)[2],+2[4],-3[4],+6[4],add(6)(p11)x2[4],+7[4],+9[3],-11[4],-12[4],-13[4],add(13)(p11)x2[4],-14[4],+15[4],-16[3],-17[4],-19[4],+20,[4],+21[4],+22[2],+mar1x2[4][cp4].


Subject(s)
Neoplasms, Fibrous Tissue/pathology , Soft Tissue Neoplasms/pathology , Aged , Aged, 80 and over , Cytogenetic Analysis , Female , Humans , Neoplasms, Fibrous Tissue/genetics , Soft Tissue Neoplasms/genetics , Thigh
8.
Cancer Genet Cytogenet ; 152(1): 56-60, 2004 Jul 01.
Article in English | MEDLINE | ID: mdl-15193442

ABSTRACT

A NUP98 gene translocation occurring with a del(6p23) and an add(11)(p15) was determined in a 61-year-old patient with therapy-related atypical chronic myelocytic leukemia after complete remission from acute promyelocytic leukemia that eventually underwent clonal evolution and transformed to CD56-positive acute myelocytic leukemia (French-American-British classification M0). Precise chromosome analysis by G-banding, spectral karyotyping analysis, and dual-color fluorescence in situ hybridization showed this abnormality as 46,XY,del(6)(p23),add(p15). ish del(6)(NUP98-,D6Z1+),der(7)(NUP98+,D7Z1+),der(11)(NUP98+,D11Z1). A split signal of NUP98 was observed in 68.4% of the 117 cells analyzed, which clearly indicated that the NUP98 partially translocated to chromosome 7. However, the potential fusion partner of the NUP98 was not HOX family or DEK. The fusion gene has not been found by a differential display method. The significance of simultaneously combined del(6)(p23), which also has been reported with secondary leukemogenesis, has not been elucidated. Additional karyotype abnormalities evolved increasingly, and leukocytosis with blasts with more complex karyotypic abnormalities appeared 5 months later. Careful and continuous analysis of karyotype change clarified the process of the clonal evolution after NUP98 translocation. Further investigation of molecular characterization of this NUP98 translocation and interaction with 6p23 abnormalities might be worthwhile for understanding leukemogenesis.


Subject(s)
Chromosome Deletion , Chromosomes, Human, Pair 11/genetics , Chromosomes, Human, Pair 6/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Leukemia, Myeloid, Acute/genetics , Neoplasms, Second Primary/genetics , Nuclear Pore Complex Proteins/genetics , Translocation, Genetic , Humans , Karyotyping , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...